Vaccines Mean Malaria Deaths Should Be Falling — Not Rising

Why It Matters

The stalled decline highlights vaccine access and financing as the decisive bottlenecks, affecting millions of children and jeopardizing global health targets.

Key Takeaways

• Cases rose to 282 million; deaths reached 610 k in 2024.
• Only 25 nations have introduced RTS,S or R21 vaccines.
• Tanzania, accounting for 4.3% of deaths, still lacks vaccine rollout.
• Gavi secured $9 billion of $12 billion target; overall funding $4 billion.
• R21 $2.99/dose; RTS,S $9.81, expected <$5 by 2028.

Pulse Analysis

The latest WHO data reveal a troubling reversal in the fight against malaria, with cases and fatalities climbing despite the availability of two proven vaccines. RTS,S, developed by GSK, cuts child infections by roughly 56%, while Oxford’s R21 shows 75% efficacy in high‑transmission zones. Yet rollout remains limited to a handful of nations, and many endemic countries—particularly in sub‑Saharan Africa—have yet to integrate these tools into national immunisation schedules. The gap between vaccine efficacy and real‑world impact underscores the importance of delivery logistics, cold‑chain capacity, and alignment with existing child‑health programs.

Financing is the linchpin holding back broader adoption. Gavi, the primary funder for low‑income vaccine programmes, fell short of its $12 billion target for 2026‑30, securing only $9 billion, while overall global malaria funding sits at $4 billion, less than half the WHO’s $8.3 billion goal. Price differentials further strain budgets: R21 is priced at $2.99 per dose, whereas RTS,S costs $9.81, though GSK aims to drop the price below $5 by 2028. These cost dynamics influence national decisions, especially in rural areas where four‑dose schedules clash with routine immunisation calendars.

To reverse the upward trend, governments, donors, and public‑health agencies must coordinate a dual strategy of scaling vaccine coverage and reinforcing traditional interventions such as insecticide‑treated nets and antimalarial drugs. Success stories from Egypt and Cabo Verde demonstrate that political will, robust surveillance, and community engagement can eradicate malaria even in resource‑constrained settings. The 2024 World Malaria Day slogan—“Now we can. Now we must.”—captures the urgency: the tools exist, but decisive investment and implementation are essential to meet the 2030 SDG target.